The U.S. Food and Drug Administration recently gave final approval to an experimental drug that experts say will save thousands of premature infants born with Respiratory Distress Syndrome.

The drug — one of an increasing number of "orphan" products that are used to treat rare diseases — is a synthetic surfactant that coats the inside of a premature infant's lungs to keep them from collapsing when the infant exhales.

This content is only available via PDF.
You do not currently have access to this content.